<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820130</url>
  </required_header>
  <id_info>
    <org_study_id>CR-12-047-FR-SC</org_study_id>
    <nct_id>NCT01820130</nct_id>
  </id_info>
  <brief_title>Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure</brief_title>
  <acronym>TAME-HF</acronym>
  <official_title>Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to evaluate the safety and efficacy of Spinal&#xD;
      Cord Stimulation (SCS) in advanced heart failure (HF) patients with Implantable Cardioverter&#xD;
      Defibrillator (ICD) but not indicated for Cardiac Resynchronization Therapy (CRT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    end of inclusion period without patient enrolled&#xD;
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Marker of Cardiac remodeling via Left Ventricular End Diastolic Volume (LVEDV) of Patient with advanced HF</measure>
    <time_frame>baseline and 6 Months</time_frame>
    <description>Evaluation of left ventricular end diastolic volume (LVEDV) as measured by cardiac echo between baseline and after 6 months of SCS therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Marker of patient symptom via NYHA class for patient with advanced HF</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Evaluation of NYHA class as marker of patient symptom between baseline and after 6 months of SCS therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Marker of patient symptom via 6 Minutes Hall Walk distance for patient with advanced HF</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Evaluation of 6 Minutes Hall walk (6MHW) as marker of patient symptom between baseline and after 6 months of SCS therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety composite marker of SCS therapy for patient with HF and ICD device</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Report of cardiovascular event, arrythmias, devices interaction, procedural and post-procedural events analyzed in a global composite way.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy markers of SCS therapy on patient symptom via Quality Of Life questionnaire</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Endpoint measurements of patient-reported quality of life after 6 months of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy markers of SCS therapy on patient symptom via Maximal exercise test tolerance</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Additional endpoint measurements include exercise tolerance between baseline and 6 months via cardiopulmonary test, including maximum level of exercise and heart rhythm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy markers of SCS therapy on cardiac function via echocardiography</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Additional endpoint measurements include standard echocardiography markers of LV structure and function including systolic and diastolic performance and cardiac dimensions as a marker of structural reverse remodeling</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Spinal Cord Stimulation system therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>St Jude Medical EON mini rechargeable system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>St Jude Medical EON mini rechargeable system</intervention_name>
    <description>implantation of Eon Mini Neurostimulation System (IPG Model 3788)</description>
    <arm_group_label>Spinal Cord Stimulation system therapy</arm_group_label>
    <other_name>Eon Mini Neurostimulation System (IPG Model 3788)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients has a Left Ventricular Ejection Fraction (LVEF) less than or equal to 35%&#xD;
&#xD;
          -  Patient is in New York Heart Association (NYHA) Class III&#xD;
&#xD;
          -  Patient has a QRS duration &lt;120 ms (non-paced QRS, at the time of device Implant or&#xD;
             protocol inclusion)&#xD;
&#xD;
          -  Patient has had an ICD implanted for &gt;90 days&#xD;
&#xD;
          -  Patient is receiving stable and optimal medical therapy for HF (&gt;90 days) as describe&#xD;
             by &quot;European Society of Cardiology 2012 recommendation for diagnosis and treatment of&#xD;
             acute and chronic Heart Failure&quot;, except in case of contraindication or allergy&#xD;
&#xD;
          -  Patient is able to provide written Informed Consent prior to any investigational&#xD;
             related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient currently has an implanted spinal cord stimulator or previously had an&#xD;
             implanted spinal cord stimulator which is now explanted or has had previous spinal&#xD;
             surgery that would interfere with implant of percutaneous SCS leads in the upper&#xD;
             thoracic region&#xD;
&#xD;
          -  Patient has polyneuropathy&#xD;
&#xD;
          -  Patient requires short-wave diathermy, microwave diathermy or therapeutic ultrasound&#xD;
             diathermy&#xD;
&#xD;
          -  Patient is in NYHA class IV&#xD;
&#xD;
          -  Patient has received a tissue / organ transplant or is expected to have a tissue /&#xD;
             organ transplant within the next 180 days&#xD;
&#xD;
          -  Patient has a cardiac resynchronization therapy (CRT) device, or LV Assist device or&#xD;
             is expected to receive CRT, or left ventricular assist device (LVAD) within the next&#xD;
             180 days&#xD;
&#xD;
          -  Patient has critical valvular heart disease that requires valve repair or replacement&#xD;
&#xD;
          -  Patient has had a myocardial infarction (MI) or cardiac revascularization procedure&#xD;
             (percutaneous coronary intervention or coronary artery bypass graft) within 90 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Patient is on IV inotropic therapy&#xD;
&#xD;
          -  Patient has active myocarditis or early postpartum cardiomyopathy&#xD;
&#xD;
          -  Patient has taken any of the following drugs within 30 days of enrollment: systemic&#xD;
             corticosteroids, cytostatic and immunosuppressive drug therapy (cyclophosphamide,&#xD;
             methotrexate, cyclosporine, azathioprine, etc.), DNA depleting or cytotoxic drugs&#xD;
&#xD;
          -  Patient is pregnant, or of childbearing potential and is not using adequate&#xD;
             contraceptive methods, or nursing&#xD;
&#xD;
          -  Patient with a bleeding tendency (INR &gt;1.2 and platelet count &lt;100 x109 per liter)&#xD;
&#xD;
          -  Patient has a local infection at the ICD implant location or systemic infection&#xD;
&#xD;
          -  Patient has renal insufficiency (creatinine &gt;3.0 mg/dl)&#xD;
&#xD;
          -  Patient with risk of allergy to SCS device component materials&#xD;
&#xD;
          -  Patient having one of the following condition must be considered as non relevant for&#xD;
             SCS implantation:&#xD;
&#xD;
               1. / Patient with active stent&#xD;
&#xD;
               2. / Patient having bare metal stent for less than 6 months&#xD;
&#xD;
               3. / Patient presented with an acute coronary syndrome within the last 6 months&#xD;
&#xD;
               4. / Patient with stent on the common&#xD;
&#xD;
               5. / Patient with a history of stent thrombosis&#xD;
&#xD;
               6. / Coronary Patient receiving double antiplatelet medication&#xD;
&#xD;
          -  Patient is participating in another clinical study with an active treatment arm&#xD;
&#xD;
          -  Patient is less than 18 years old&#xD;
&#xD;
          -  Patient's life's expectancy is less than 1 year as assessed by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Bordachar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

